Prevention of Perinatal Hepatitis B TransmissionReview Published on 2023-06-012023-06-12 Journal: Obstetrics and gynecology clinics of North America [Category] B형 간염, [키워드] hepatitis B Perinatal Postexposure Prophylaxis prevention vaccination. [DOI] 10.1016/j.ogc.2023.02.007 PMC 바로가기 [Article Type] Review
Effectiveness of varicella vaccination during an outbreak in a large one-dose-vaccinated population in ShanghaiArticle Published on 2022-12-302023-05-31 Journal: Human vaccines & immunotherapeutics [Category] 두창, 수두, 홍역, [키워드] Emergency vaccination outbreak Postexposure Prophylaxis vaccine effectiveness Varicella vaccine. [DOI] 10.1080/21645515.2022.2143176 PMC 바로가기
Monkeypox after Occupational Needlestick Injury from PustuleCase Reports Published on 2022-12-012023-06-09 Journal: Emerging Infectious Diseases [Category] Fulltext, 원숭이두창, [키워드] Emerging communicable diseases injuries Monkeypox Monkeypox virus MPXV Needlestick injury occupational exposure Portugal Postexposure Prophylaxis pustule viruses zoonoses. [DOI] 10.3201/eid2812.221374 PMC 바로가기 [Article Type] Case Reports
Detection and Kinetics of Subgenomic Severe Acute Respiratory Syndrome Coronavirus 2 RNA Viral Load in Longitudinal Diagnostic RNA-Positive SamplesArticle Published on 2022-09-132022-11-15 Journal: The Journal of Infectious Diseases [Category] SARS, 치료기술, [키워드] Above acute respiratory syndrome characterized collected coronavirus coronavirus 2 COVID-19 detectable detection diagnostic duration of illness identify independent Kinetics large sample linear load longitudinal nasal swab nucleic acid amplification participant peaking polymerase chain Postexposure Prophylaxis replicating virus Replication respiratory RNA RT-PCR Sample SARS-CoV-2 sgRNA sgRNAs subgenomic RNA swab sample Symptom threshold trajectory Treatment Viral load Viral load. viral replication Viral RNA while [DOI] 10.1093/infdis/jiac048 PMC 바로가기
Fair Allocation of Scarce Therapies for Coronavirus Disease 2019 (COVID-19)코로나바이러스 질병 2019(COVID-19)에 대한 희소한 치료제의 공정한 할당Article Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 변종, [키워드] ad hoc allocation antiviral drug antiviral drugs antivirals approach asked bioethics category Clinical risk factors Community coronavirus disease Coronavirus disease 2019 COVID-19 delta variant disease doses drug Emergency use authorization EUA exclusion Factor Fair FDA food Government group Health health inequities healthcare identify Immunocompromise Inclusion individual mAbs Mild moderate molnupiravir monoclonal monoclonal antibodies monoclonal antibody Older age omicron Omicron variant Patient Paxlovid Postexposure Prophylaxis rationing required scarcity supply Therapies therapies. therapy US Food and Drug Administration vaccination variant [DOI] 10.1093/cid/ciab1039 PMC 바로가기 [Article Type] Article
How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies혈액암 환자와 세포 요법을 받는 환자의 COVID-19 치료 및 예방 방법Article Published on 2022-08-182022-09-11 Journal: Blood [Category] SARS, 변종, 임상, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration approach attenuate breakthrough infections Cell Cell therapy cell transplantation cellular therapy circulating circulating SARS-CoV-2 variants Clinical efficacy coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 in patient COVID-19 vaccine COVID-19 vaccines Drug-drug interactions Factors General population HCT Hematologic malignancy Hematopoietic cell transplantation higher risk Host Humoral response increased risk Infection morbidity morbidity and mortality Patient Postexposure Prophylaxis practicality Prevent progression recipient recipients SARS-CoV-2 Selection severe acute respiratory syndrome Coronavirus severe coronavirus disease severe COVID-19 Side effects therapeutic Therapies therapy treat Treatment virus [DOI] 10.1182/blood.2022016089 PMC 바로가기 [Article Type] Article
COVID-19 in patients with hematologic malignancy혈액암 환자의 코로나19Article Published on 2022-07-212022-09-11 Journal: Blood [Category] Coronavirus, COVID19(2023년), SARS, 변종, 치료제, [키워드] active immunization acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 advanced age Antibody Response Antiviral antiviral drug antiviral drugs Clinical efficacy contribute coronavirus COVID-19 COVID-19 in patient develop early treatment early treatment of COVID-19 hematologic Hematologic malignancy heterogeneity high risk illnesses immune response immune system Infectious disease malignancy MONITOR monoclonal antibodies monoclonal antibody mortality rate offered outcome pandemic Patient patients hospitalized Postexposure Prophylaxis predict Prevent reduced risk factor SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 vaccine SARS-CoV-2 vaccines severe acute respiratory syndrome Coronavirus severe COVID-19 significantly subtype symptomatic therapy Treatment vaccination Vaccine variants virus [DOI] 10.1182/blood.2021012251 PMC 바로가기 [Article Type] Article
Pharmacist responsiveness and readiness for oral antivirals for COVID-19: A rebuttal to the AMA statement regarding the Biden administration’s test-to-treat planCOVID-19에 대한 경구용 항바이러스제에 대한 약사의 반응 및 준비: 바이든 행정부의 시험-치료 계획에 관한 AMA 성명에 대한 반박Article Published on 2022-07-012022-09-11 Journal: Journal of the American Pharmacists Association : [Category] 치료제, [키워드] administration AMA Antiviral antiviral therapy approach Clinical practice complex coronavirus disease Coronavirus disease 2019 COVID-19 disease effort health system health systems mass vaccination medical association mitigate offset Pharmacist positive test result Postexposure Prophylaxis Prescriptions Prophylaxis released test result therapy treat Treatment vaccination [DOI] 10.1016/j.japh.2022.03.023 PMC 바로가기 [Article Type] Article
Ivermectin for preventing and treating COVID-19COVID-19 예방 및 치료를 위한 이버멕틴Review Published on 2022-06-212022-09-11 Journal: The Cochrane database of systematic reviews [Category] COVID19(2023년), SARS, 임상, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition Admission adverse event adverse events all-cause mortality antiparasitic Antiviral approach ARMS Asymptomatic certainty certainty of evidence citation classification Clinical improvement clinical trial Cochrane COVID-19 Study Register coronavirus coronavirus disease COVID-19 COVID-19 diagnosis COVID-19 symptoms COVID-19 treatment Data collection database death discharged disease disease severity double-blind duration of symptom early stage early stages Efficacy Efficacy and safety eligible Evidence excluded for inclusion GRADE hospital identify in vitro include increase index Infection infection with SARS-CoV-2 inhibit inhibitory effect initial symptom Inpatient Inpatients Intervention Invasive mechanical ventilation investigated Ivermectin life mean difference Mental Meta-analysis Mild Moderate COVID-19 moderate-to-severe COVID-19 molecular hypothesis Mortality no effect non-randomized ongoing trial ongoing trials Open-label outcome Outpatient outpatients participant Participants people with COVID-19 physical Placebo placebo-controlled Postexposure Prophylaxis Prevent Quality of life question Randomized controlled trial Randomized controlled trials RCT RCTs receiving reduce Registered Replication Reporting request Research resolved risk Risk of bias risk ratio RoB 2 SARS-CoV-2 SARS-COV-2 infection Science Citation Index searched Selection Serious Adverse Event Serious Adverse Events Seven severe acute respiratory syndrome Coronavirus Standard of care treat treated treating COVID-19 Treatment Trial trials viral clearance virus Web of Science WHO WHO guideline worsening [DOI] 10.1002/14651858.CD015017.pub3 PMC 바로가기 [Article Type] Review
Estimated Health Outcomes and Costs of COVID-19 Prophylaxis With Monoclonal Antibodies Among Unvaccinated Household Contacts in the US미국에서 백신 접종을 하지 않은 가족 중 단클론 항체를 사용한 COVID-19 예방의 예상 건강 결과 및 비용Randomized Controlled Trial Published on 2022-04-012022-09-11 Journal: JAMA Network Open [Category] COVID19(2023년), SARS, 변종, 임상, 진단, [키워드] Administered age Casirivimab complementary confirmed COVID-19 case Contact Coverage COVID-19 COVID-19 case COVID-19 infection COVID-19 infections COVID-19 pandemic COVID-19 vaccination death deaths disrupt effective vaccine Effective vaccines eligible Estimated Ethnicity exposure to Health health system Hospitalization hospitalizations household household contact Imdevimab IMPROVE individual Infection intensity mAb mAbs monoclonal antibodies monoclonal antibody Older outcome Postexposure Prophylaxis Probability public health randomized clinical trial reduce reduce costs Sex subcutaneous injection subcutaneous injections susceptible symptomatic infection symptomatic infections threshold thresholds Transmission Vaccination Status Vaccine variant of SARS-CoV-2 [DOI] 10.1001/jamanetworkopen.2022.8632 PMC 바로가기 [Article Type] Randomized Controlled Trial